
Delivering Innovation to the EyeTM
Focused on developing and commercializing innovative ophthalmic products and technologies for serious ophthalmic diseases
About EyePoint
Latest EyePoint News
- EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
- EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
- EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
- EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors
- EyePoint Pharmaceuticals Provides 2019 Commercial Update